We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Artificial Skin Graft Replaces Damaged Skin

By HospiMedica staff writers
Posted on 16 Jul 2007
A new study reports on the first laboratory-manufactured human skin graft that has demonstrated full, consistent wound integration and persistence. More...


In a Phase I trial study, a full-thickness skin sample was excised from the upper arm of six volunteers and replaced with ICX-SKN, a skin graft replacement composed of an autosynthesized human collagen-based extracellular matrix and human dermal fibroblasts.

After 28 days both visual and histological analysis showed that in all volunteers the ICX-SKN grafts were rapidly vascularised and overgrown with the hosts' own cells, resulting in a fully integrated skin graft that had closed and healed the wound site.

ICX-SKN, which shares many of the structural attributes of skin, is under development by Intercytex (Cambridge, United Kingdom). The skin graft contrasts with other living skin graft alternatives, which biodegrade in situ after a matter of weeks. The developers believe that the combination of living human fibroblasts in a human fibroblast-produced matrix underpins the integration and acceptance of ICX-SKN by the host skin. The study was published in the July 2007 issue of the journal Regenerative Medicine.

Intercytex intends to develop a range of cell-based implants that can regenerate lost tissue and this research is an important milestone in the pursuit of that objective, said lead author Dr. Paul Kemp, Intercytex' founder and chief scientific officer. For regenerative medicine to fulfill its promise, scientists need to develop cellular implants that are accepted and integrated into the human body. So far this has proved elusive but today's research shows, for the first time, that it can be achieved.

I think these results are a real breakthrough in the field of wound healing and regenerative medicine in general, said Dr Stephen L Minger, director of the stem cell biology laboratory at King's College London (United Kingdom), and senior editor of Regenerative Medicine. To have an off-the-shelf skin replacement product that can be used in large numbers of patients will revolutionize the treatment of burned and skin damaged patients.


Related Links:
Intercytex
King's College London

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.